Merck & Cie

Merck Patent Gmbh

Eprova Ag

Biomarin Pharmaceutical Inc.

Merck Eprova Ag

Eprov A.g.

Bayer Intellectual Property Gmbh

Mereck & Cie

Bayer Pharma Aktiengesellschaft

Bayer Schering Pharma Ag

Rudolf Moser

Viola Groehn

Fritz Blatter

Thomas Egger

Thomas Ammann

Martin Szelagiewicz

Simon Mensah Ametamey

Ruth Boehni Stamm

Roger Schibli

Tobias Ludwig Ross

Emil D Kakkis

Martin Ulmann

Fredric D Price

Alejandro Dorenbaum

Hans R Muller

Daniel I Oppenheimer

Cristina Magdalena Muller

Markus Ruettimann

Giuseppe Lapadula

Cindy Ramona Fischer

Hans Rudolf M&uuml;ller

Cristina Magdalena Mueller

Pierre Martin

Benoit Pugin

Andreas Schumacher

Kristina King

Dirk Spielvogel

Thomas Leighton Mindt

Rudolf M&uuml;ller

Simon Ametamey

Silvan Boss

Cristina Mueller

Phoebe Lam

Ton J Rabelink

Tom J Rabelink

Harriet Struthers

Kai Strothmann

Gavin Welch Wasserfall-Smith

Klaus Pietrzik

Thomas Betzel

Hans Rudolf Müller

Gavin Smith

Cristina Magdalena MÜLLER

Keith M Channon

Charalambos Antoniades

Cheerag Shirodaria

Gavin Welch Smith

The present invention is directed to a crystalline salt of 5-methyl-(6S)-tetrahydrofolic acid and L-isoleucine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to L-isoleucine ethyl ester is from 1:0.3 to 1:2.0 (in mol/mol) and/or hydrates and/or solvates thereof, as well as, a process of obtaining the same.

Crystalline salt of 5-methyl-(6S)-tetrahydrofolic acid and L-isoleucine ethyl ester

The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and an amino acid ethyl ester like L-phenylalanine ethyl ester or L-methionine ethyl ester, wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to amino acid ethyl ester is from 1:0.3 to 1:3.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.

Crystalline salts of 5-methyl-(6S)-tetrahydrofolic acid and amino ethyl esters

The present invention is directed towards the hemisulfate salt of 5,10-methylene-(6R)-tetrahydrofolic acid, preferably in substantially crystalline form, as well as pharmaceutical compositions and uses thereof in therapy, preferably chemotherapy.

Stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid

The invention is directed towards stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid and its hemisulfate salt as well as pharmaceutical compositions and uses thereof in therapy, preferably chemotherapy.

Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid

Crystalline monosodium salt of 5-methyl-(6S)-tetrahydrofolic acid wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to sodium is from 1:0.5 to 1:1.5 (in mol/mol) and/or hydrates and/or solvates thereof, their use as pharmaceuticals, as well as processes of obtaining the same.

Crystalline monosodium salt of 5-methyl-(6S)-tetrahydrofolic acid

The present invention is directed towards isomerically pureF-labelled (6S)- or (6R)-5-methyltetrahydrofolate radiopharmaceuticals, wherein the phenyl group within the folate structure, has been replaced by anF-labelled N-heterocycle, for use in diagnostic imaging of a cell or population of cells expressing a folate-receptor in vitro or in vivo or for use in monitoring of cancer or inflammatory and autoimmune diseases and therapy thereof.

Isomerically pureF-labelled tetrahydrofolates

The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and L-valine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid and L-valine ethyl ester is from 1:0.3 to 1:3.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.

Crystalline salts of 5-methyl-(6S)-tetrahydrofolic acid and L-valine ethyl ester

The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid L-leucine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid and L-leucine ethyl ester is from 1:0.3 to 1:3.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.

Crystalline salts of 5-methyl-(6S)-tetrahydrofolic acid and l-leucine ethyl ester

The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and 4-(2-hydroxyethyl)-morpholine wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to 4-(2-hydroxyethyl)-morpholine is from 1:0.3 to 1:2.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.

Crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and 4-(2-hydroxyethyl)-morpholine

The present invention is directed to a crystalline sodium salt of 5-methyl-(6S)-tetrahydrofolic acid wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to sodium is from 1:1.51 to 1:2.5 and/or hydrates and/or solvates thereof, as well as, a process of obtaining the same.

Crystalline sodium salt of 5-methyl-(6S)-tetrahydrofolic acid

The present invention is directed to stable lyophilisates comprising 5,10-methylene-(6R)-tetrahydrofolic acid or a pharmaceutically acceptable salt thereof and a dicarboxylic acid, or a salt thereof, as well as, a processes of obtaining the same, and the use of such products.

Stable lyophilisates comprising 5,10-methylene-(6R)-tetrahydrofolic acid

The present invention is directed to a crystalline sodium salt of 5-methyl-(6S)-tetrahydrofolic acid wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to sodium is from 1:0.5 to 1:1.5 (in mol/mol) and/or hydrates and/or solvates thereof, as well as, a processes of obtaining the same.

The present invention is directed to crystalline salt of 5-methyl-(6S)-tetrahydrofolic acid comprising

Crystalline binary sodium salts of 5-methyl-(6S)-tetrahydrofolic acid with organic bases

The present invention is directed towards newF-folate radiopharmaceuticals, wherein theF isotope is linked via a prosthetic group, more specifically via a prosthetic group having a saccharide group, such as a cyclic mono- or oligosaccharide, preferably based on a pyranoside or furanoside, which is covalently linked to the glutamate portion of a folate or derivative thereof, a method of their preparation, as well as their use in diagnosis and monitoring of cancer and inflammatory and autoimmune diseases and therapy thereof.

F-saccharide-folates

Growing community of inventors

Schaffhausen, Switzerland

Rudolf Moser